Nationwide Children's Research News
Viewing: 41-50 of 385 | All
Nov 16, 2023
Study Shows Amount and Days of Opioids Prescribed at Discharge Decreased After 2017 Ohio Prescription Opioid Cap Law
In a new study, published in PLOS One, researchers at the Center for Injury Research and Policy, Center for Pediatric Trauma Research, Department of Pediatric Surgery, Department of Pediatrics, Department of Orthopedics, and Department of Anesthesiology and Pain Medicine at Nationwide Children’s Hospital compared the amount of opioid analgesics prescribed to children following enactment of the Ohio Opioid Cap Law with historical controls.
Oct 23, 2023
Probiotics Delivered in Biofilm State Protect the Intestines and Brain in NEC Model
Researchers at Nationwide Children’s have been working on a novel solution to prevent NEC. They have developed a novel probiotic system that harnesses the durability of biofilms to improve the administration of probiotics to patients. It has been licensed to Scioto Biosciences. Their latest study, published in Nature Scientific Reports, describes the use of a biofilm formulation of Limosilactobacillus reuteri (Lr) to prevent NEC in a piglet model.
Oct 18, 2023
Nationwide Children's Hospital to Expand Mental and Behavioral Health Research
Nationwide Children's Hospital has created a new Institute for Mental and Behavioral Health Research, significantly expanding opportunities to seek a better understanding of mental and behavioral health in children and to develop better diagnostics, treatment and preventative strategies. Leading this new institute will be Eric Youngstrom, PhD, a nationally renowned psychologist specializing in the relationship of mood and psychopathology, and the clinical assessment of children and families.
Oct 09, 2023
Study Finds GERD Less Likely Cause of Fussiness in Irritable Infants
In a new study published in The Journal of Pediatrics, researchers in the Abigail Wexner Research Institute at Nationwide Children’s Hospital have found that high-risk infants who express irritability and arching of their backs likely are not suffering from gastroesophageal reflux disease (GERD).
Sep 18, 2023
Study Shows Nearly 300% Increase in ADHD Medication Errors
In a new study, published today in Pediatrics, researchers at the Center for Injury Research and Policy and Central Ohio Poison Center at Nationwide Children’s Hospital investigated the characteristics and trends of out-of-hospital ADHD medication errors among people younger than 20 years old reported to U.S. poison centers from 2000 through 2021.
Sep 13, 2023
Nationwide Children’s, Ohio State Receive $17.7 Million to Study Children’s Health
A research team at Nationwide Children’s Hospital and The Ohio State University Wexner Medical Center was recently awarded $17.7 million from the National Institutes of Health (NIH) to join a national consortium to study how childhood environments and experiences influence the health of children as they grow and develop.
Sep 11, 2023
$6.95 Million FDA Grant to Help Create Medical Devices Just for Children
The Food and Drug Administration (FDA) announced a $6.95 million grant to be distributed over five years to create a new consortium led by investigators from Nationwide Children’s Hospital, The Ohio State University, Cleveland Clinic Children’s, and Cincinnati Children’s to help increase the number of pediatric medical devices across the nation.
Aug 08, 2023
From Bench to Bedside: Patient with Duchenne Muscular Dystrophy Receives First Dose of Gene Therapy Developed at Nationwide Children’s Hospital
In a landmark moment for the Abigail Wexner Research Institute at Nationwide Children’s, a 5-year-old from Bellefontaine, Ohio, received the first dose of a recently approved gene therapy for Duchenne muscular dystrophy at Nationwide Children’s Hospital, where the therapy was invented and initially tested.
Jun 22, 2023
FDA Approves First Gene Therapy Treatment for Duchenne Muscular Dystrophy Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of SRP-9001/ELEVIDYS for Duchenne muscular dystrophy (DMD) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
Jun 13, 2023
Mapping the 3D Structure of Rhabdomyosarcoma Chromatin
In a paper published in Nucleic Acids Research Cancer (NAR Cancer), researchers from the Center for Childhood Cancer Research at Nationwide Children’s and their collaborators report a comprehensive 3D chromatin structural analysis and characterization of rhabdomyosarcoma (RMS).